Belite Bio Inc ADR

Price Chart

Risk-Adjusted Performance

Belite Bio Inc ADR (BLTE) Price Performance

Belite Bio Inc ADR (BLTE) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $165.45, up 4.68% from the previous close.

Over the past year, BLTE has traded between a low of $56.81 and a high of $190.30. The stock has gained 183.4% over this period. It is currently 13.1% below its 52-week high.

Belite Bio Inc ADR has a market capitalization of $6.46B.

About Belite Bio Inc ADR

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Compare Belite Bio Inc ADR

Side-by-side comparison against top Healthcare peers.